Novartis has entered into a collaboration with Pear Therapeutics to develop novel prescription digital therapeutics, software applications designed to effectively treat disease and improve clinical outcomes for patients. The collaboration brings together Novartis expertise in biomedical research and clinical development with Pear’s leading experience in digital therapeutics design and implementation. http://www.worldpharmanews.com/novartis/4311-novartis-and-pear-therapeutics-to-develop-digital-therapeutics-for-patients-with-schizophrenia-and-multiple-sclerosis
Trishna Bharadia, Multiple Sclerosis patient advocate, wants to make MS care more patient-centric.
The post 5 questions: making Multiple Sclerosis care more patient-centric appeared first on Pharmaphorum. https://pharmaphorum.com/views-and-analysis/multiple-sclerosis-patient-centric/
EAST HANOVER, N.J., Aug. 21, 2017 /PRNewswire/ — Novartis announced today the launch of a mobile research study for people with multiple sclerosis (MS) that collects data via their smartphone, without the need for clinic visits. The study, Evaluation of Evidence from Smart Phone Sensors… http://www.prnewswire.com/news-releases/novartis-launches-first-large-scale-research-study-in-multiple-sclerosis-that-allows-participants-to-contribute-from-smartphones-300506716.html
SAN JUAN, Puerto Rico, July 27, 2017 /PRNewswire/ — Abarca Health, a pharmacy benefit management (PBM) and technology company that serves more than two million lives across the nation, has signed a value-based reimbursement contract with Biogen Inc. (NASDAQ: BIIB) for select products in… http://www.prnewswire.com/news-releases/abarca-health-and-biogen-announces-innovative-value-based-contract-for-multiple-sclerosis-therapies-300495565.html
The positive data for Roche’s Ocrevus keep on coming. Friday, the company’s Genentech unit announced that the multiple-sclerosis fighter had significantly cut down disease activity and disability progression in patients with relapsing forms of the disease and those with the harder-to-treat, primary progressive forms. http://www.fiercepharma.com/marketing/roche-s-ocrevus-racks-up-more-positive-ms-data-relapsing-and-primary-progressive-forms
Celgene reported Monday that an experimental pill for the main type of multiple sclerosis met its main goals in a two-year study. By the end of the year, the Summit, NJ, drugmaker will ask the FDA to consider the drug, ozanimod, for approval. The Celgene (NASDAQ: CELG) drug is being tested in patients with relapsing […] http://www.xconomy.com/new-york/2017/05/22/celgenes-data-could-lead-to-new-option-for-multiple-sclerosis-patients/
Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be key in the onset of multiple sclerosis.
read more http://www.pharmafile.com/news/513890/breakthrough-multiple-sclerosis-research-sheds-light-cause-disease
The current topic of discussion regarding NICE is how its recent changes will impact patient access to medicine but, away from the headlines, the body continues to perform its role of determining which medicines will be available to patients. In this case, it has approved Biogen’s Zinbryta for patients suffering from relapsing remitting multiple sclerosis, though with the caveat of there being particular circumstances dependent for its use.
read more http://www.pharmafile.com/news/513589/nice-reverses-decision-medication-relapsing-multiple-sclerosis